Related Experiment Video
Updated: Jun 25, 2025
A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors
Published on: March 15, 2016
Rational Drug Discovery for Isoxazole Based VEGFR2 Inhibition
Shital M Patil1, Indrani Mahadik1, Shashikant V Bhandari1
1Department of Chemistry, AISSMS College of Pharmacy, Kennedy Road, Pune, 01, India.
Background:
Inhibiting receptor-tyrosine-kinase (RTK) signalling pathways has emerged as a key focus of novel cancer therapy development. Vascular endothelial growth factor receptor (VEGFR) is a member of the RTK family and is required for vasculogenesis and angiogenesis. Because VEGFR 2 is the subtype responsible for cellular angiogenesis and vasculogenesis, blocking it will impair tumour cell blood supply, reducing their development, proliferation, and metastasis.
Aim & Objective:
The aim of this study is to obtain an optimised pharmacophore as a VEGFR2 inhibitor using QSAR investigations. This aids in determining the link between structure and activity in new chemical entities (NCEs).
Materials And Methods:
The multi-linear regression approach (MLR) method was utilised to generate the QSAR Model using the programme QSARINS v.2.2.4.
Results And Discussion:
For 2D QSAR, the best models produced has correlation coefficients of R2= 0.9396. The 3D-QSAR model obtained with R2= 0.9121 and Q2 = 0.8377. Taking docking observations, pharmacological behaviour, and toxicity analyses into account, most of the derivatives demonstrated VEGFR2 inhibitory competence.
Conclusion:
According to QSAR studies, more electron-donating groups on the benzene ring linked to the isoxazole were shown to be necessary for activity. In molecular docking studies, most compounds have shown stronger affinity for the crucial amino acids Cys:919, Asp:1046, and Glu:885, which are found in typical drugs. All NCEs passed the Lipinski screening.
Insights
Quantitative Structure-Activity Relationship (QSAR) studies identified key structural features for potent Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) inhibitors. These optimized compounds show promising anti-cancer potential by blocking tumor angiogenesis and metastasis.
Area of Science:
- Medicinal Chemistry
- Computational Chemistry
- Cancer Therapeutics
Background:
- Receptor-tyrosine-kinase (RTK) signaling pathways are crucial targets in cancer therapy.
- Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) is essential for tumor angiogenesis and metastasis.
- Inhibiting VEGFR2 can impede tumor growth and spread.
Purpose of the Study:
- To develop an optimized pharmacophore for VEGFR2 inhibition using Quantitative Structure-Activity Relationship (QSAR) analysis.
- To elucidate the relationship between chemical structure and VEGFR2 inhibitory activity for new chemical entities (NCEs).
Main Methods:
- Quantitative Structure-Activity Relationship (QSAR) modeling was performed using the multi-linear regression (MLR) approach.
- QSARINS v.2.2.4 software was utilized for model generation.
- Molecular docking studies were conducted to assess binding affinities.
Main Results:
- 2D QSAR models achieved a high correlation coefficient (R²=0.9396).
- 3D QSAR models demonstrated strong predictive power (R²=0.9121, Q²=0.8377).
- Most derivatives exhibited significant VEGFR2 inhibitory potential, supported by docking and toxicity analyses.
Conclusions:
- Electron-donating groups on the benzene ring attached to the isoxazole moiety enhance VEGFR2 inhibitory activity.
- Compounds showed high affinity for key amino acids (Cys:919, Asp:1046, Glu:885) in VEGFR2.
- All investigated new chemical entities (NCEs) adhered to Lipinski's rule of five, indicating favorable pharmacokinetic properties.
Related Concept Videos
01:26Drug Discovery: Overview
01:28Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
01:24Regulation of Angiogenesis and Blood Supply